Agenus Inc. (NASDAQ:AGEN) Insider Christine M. Klaskin Sells 11,120 Shares

Agenus Inc. (NASDAQ:AGEN) insider Christine M. Klaskin sold 11,120 shares of Agenus stock in a transaction on Friday, September 10th. The shares were sold at an average price of $6.50, for a total transaction of $72,280.00. The sale was disclosed in a document filed with the SEC, which is available through this link.

NASDAQ:AGEN opened at $5.59 on Wednesday. The firm has a market capitalization of $1.30 billion, a PE ratio of -4.99 and a beta of 1.35. Agenus Inc. has a 1 year low of $2.50 and a 1 year high of $6.79. The firm’s fifty day simple moving average is $5.80 and its 200 day simple moving average is $4.45.

Agenus (NASDAQ:AGEN) last issued its quarterly earnings results on Sunday, August 8th. The biotechnology company reported ($0.37) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.24) by ($0.13). Equities analysts anticipate that Agenus Inc. will post -0.28 EPS for the current fiscal year.

Hedge funds and other institutional investors have recently modified their holdings of the business. Point72 Asset Management L.P. bought a new stake in shares of Agenus in the first quarter valued at approximately $7,164,000. Great Lakes Advisors LLC acquired a new position in Agenus during the 2nd quarter valued at $13,641,000. Vanguard Group Inc. boosted its holdings in Agenus by 17.9% in the 2nd quarter. Vanguard Group Inc. now owns 13,903,405 shares of the biotechnology company’s stock valued at $76,329,000 after purchasing an additional 2,109,183 shares during the period. BlackRock Inc. grew its position in Agenus by 13.3% in the 2nd quarter. BlackRock Inc. now owns 16,145,203 shares of the biotechnology company’s stock worth $88,638,000 after purchasing an additional 1,893,291 shares during the last quarter. Finally, Millennium Management LLC increased its holdings in shares of Agenus by 37.9% during the 2nd quarter. Millennium Management LLC now owns 5,636,579 shares of the biotechnology company’s stock worth $30,945,000 after purchasing an additional 1,549,205 shares during the period. 49.28% of the stock is currently owned by institutional investors.

AGEN has been the subject of a number of recent research reports. B. Riley upped their price objective on shares of Agenus from $11.00 to $12.00 and gave the stock a “buy” rating in a report on Tuesday, September 7th. Zacks Investment Research downgraded Agenus from a “buy” rating to a “hold” rating in a research note on Tuesday, August 10th.

About Agenus

Agenus, Inc is a clinical-stage immuno-oncology company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, and AGEN1777. The company was founded by Garo H. Armen and Pramod K.

Featured Story: Is it Safe to Invest in Commodities?

Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.